Dr. Daniel Tietjen

Daniel Tietjen is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. His focus is on litigation and legal advice to national and international companies, particularly in all areas of pharmaceutical law, medical device law, unfair competition law and intellectual property law including trademark law.

CV

Since 2017 Lawyer, Taylor Wessing

2012 – 2017 Lawyer, Hogan Lovells International LLP

2009 – 2012 Legal counsel, Centre for Protection against Unfair Competition (Wettbewerbszentrale)

Carrière

Since 2017 Lawyer, Taylor Wessing

2012 – 2017 Lawyer, Hogan Lovells International LLP

2009 – 2012 Legal counsel, Centre for Protection against Unfair Competition (Wettbewerbszentrale)

Publications

Possible ban on the mail-order of prescription-only (Rx) medicinal products in Germany, Dr. Daniel Tietjen, March 2018
Software als Medizinprodukt, Dr. Daniel Tietjen, Zeitschrift für Stoffrecht Jahrgang 15, Ausgabe 1 (2018) pp. 19 - 21
Dynamische und personalisierte Preise: Welche lauterkeitsrechtlichen Schranken gelten für Unternehmen?, in: GRUR-Prax 2017, 546 (zusammen mit Dr. Benedikt F. Flöter)
„Das System des gemeinschaftsrechtlichen Staatshaftungsrechts“, Duncker & Humblot, Berlin, 2010
„Die Bedeutung der deutschen Richterprivilegien im System des gemeinschaftsrechtlichen Staatshaftungsrechts“, EWS 2007, 15

Langues étrangères

Prix et distinctions

Legal 500 2025

Featured

Legal 500 2025

JUVE 2024/2025

Experience

NORD Holding on the acquisition of Zentrum Gesundheit Group

NORD Holding, a leading private equity house, on the acquisition of the majority interest in Zentrum Gesundheit Group, a leading German group of ophthalmic surgery and diagnostic centres, from Waterland Private Equity. NORD Holding, together with the management and medical team, acquired a stake as a new partner and majority shareholder. In this deal the Taylor Wessing team again demonstrated its interdisciplinary expertise in the areas of healthcare M&A, regulatory and acquisition financing.

Press release

Dr. Oliver Kirschner

Dr. Oliver Klöck

Ulf Gosejacob

Maria Weiers

Dr. Anne Steinhardt

Christopher Peine

Dr. Michael Beyer, Dipl.-Volkswirt

Dr. Vanessa Christin Vollmar

Dr. Lars Hagen

Dr. Marco Hartmann-Rüppel, Dipl.-Volkswirt

Dr. Michael Brüggemann

Thanos Rammos, LL.M.

Dr. Daniel Tietjen

Actualités et publications récentes

View Daniel's insights

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Reform of the Veterinary Medicines Act

13 octobre 2025

par Dr. Daniel Tietjen et Daniel Dietrich

Synapse - Europe's approach to supply chain issues for medicines and medical devices

Comparison of national measures to protect the supply of medicines and medical devices

Our international team has developed a practical guide that allows users to navigate different European jurisdictions, identifying medicines subject to supply restrictions, and understand manufacturers' obligations during shortages or product withdrawals.

1 octobre 2025

par plusieurs auteurs

5 de 5 Publications

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Rx bonus decision by the German Federal Court of Justice (BGH): German drug pricing law not applicable to EU mail-order pharmacies

26 septembre 2025

Briefing

par Dr. Daniel Tietjen et Ennio Schwind, LL.M. Eur.

Cliquer ici pour en savoir plus

Dr. Daniel Tietjen

Legal 500 2025

Expertise

Services et Groupes

Secteurs